CDK9-Cyclin T1 PPI-IN-1

• CAS Number:

  2995336-58-6

• UNSPSC Description:

  CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC50: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model[1].

• Target Antigen:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-cyclin-t1-ppi-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=C(C=C1)C(NC2=CC(C3=CC(N4CCC(CC4)O)=NC=C3)=CC=N2)=O

• Molecular Weight:

  404.46

• References & Citations:

  [1]Gao G, et al. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. Eur J Med Chem. 2023 Oct 6;261:115858.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported